Back to search results

GLYLO Supplement Pilot Trial for Glycation and Aging in Postmenopausal Women

This study is testing a dietary supplement called GLYLO in postmenopausal women aged 45 to 65 who are overweight or obese. GLYLO contains ingredients like Benfotiamine, Vitamin B6, Nicotinamide, and Alpha Lipoic Acid. The researchers want to see if GLYLO can lower levels of advanced glycation end products (AGEs), which are harmful compounds linked to aging and disease. They also hope to improve metabolic and hormonal health and reduce age-related decline. You would be compared to a group receiving a placebo (an inactive capsule). The study aims to enroll 30 participants.

Study design
This is an interventional pilot study involving 30 postmenopausal women. Participants will receive either GLYLO or a placebo.
What's involved
You would have one screening visit and three testing visits over a 6-month period. Each visit requires fasting for at least 10 hours and involves blood draws, measurements of height, weight, and vital signs.
Compensation
Not stated in the trial record.
Follow-up
The primary outcomes, Methylglyoxal (MGO) and Advanced Glycation End Products (AGEs), are measured at Baseline, Week 12, and Week 24.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06813261

GLYLO Supplement Pilot Trial on Glycation and Aging in Postmenopausal Women

Recruiting
NAAges 45–65Interventional
Buck Institute for Research on Aging
~30 participants
Updated 2025-09-08 on ClinicalTrials.gov
What's tested:GLYLOPlacebo

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Methylglyoxal (MGO)
Measured over Baseline, Week 12, Week 24
+1 more outcome measured

Conditions

Postmenopause
Metabolism
Geroscience

Explore related trials

Metabolic SyndromePostmenopausalHemoglobin A1C Measurement

Where it's being run

1 sites across 1 states
California1

Who to contact

Brianna Stubbs, DPhil
[email protected]
415-209-2000 · ext. 6709
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

BMI ≥ 25 kg/m², based on self-reported weight and height
OR Waist circumference ≥88 cm, based on self-measured values. Participants may provide average home weight measurements over two consecutive days if their BMI at the screening visit is slightly below 25 kg/m². 5. HbA1c 5.5- 6.4% (screening measurement) 6. Able to read and speak English well enough to provide informed consent and understand instructions. 7. Able to attend in-person visits at The Buck Institute

What this trial measures

  • Methylglyoxal (MGO)Baseline, Week 12, Week 24

    MGO is a reactive dicarbonyl compound, measured by biochemical assays such as high-performance liquid chromatography (HPLC) or liquid chromatography-mass spectrometry (LC-MS) . The concentration of MGO is quantified to assess its role in the formation of advanced glycation end products (AGEs). Change is measured across the study

  • Advance glycation end products (AGE)Baseline, Week 12, Week 24

    Measurement of circulating and tissue-bound AGE will be measure by either HPLC or LC-MS. Change is measured across the study